NCT06221059View on ClinicalTrials.gov

Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

March 2, 2024

Primary Completion Date

March 5, 2025

Study Completion Date

June 30, 2025

Conditions
Chronic Kidney Disease
Interventions
DRUG

HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo

Drug：HRS-1780 tablet Drug：Henagliflozin Proline tablet Drug：HRS-1780 tablet placebo Drug：Henagliflozin Proline tablet placebo

Trial Locations (1)

210002

General Hospital of Eastern Theater Command, Nanjing

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY